Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dextromethorphan Polistirex

FDA-approved product (suspension, extended release, oral), marketed as Delsym, Dextromethorphan Polistirex.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dextromethorphan Polistirex
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic disease
  • Common cold
  • Cough
  • Fever
  • Headache
  • Nasal congestion
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other nervous system drugs; Opium alkaloids and derivatives
FDA pharmacologic class
Sigma-1 Agonist; Uncompetitive N-methyl-D-aspartate Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dextromethorphan Polistirex in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dextromethorphan Polistirex with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

    NCT03420469 · start 2018-06-05

    Registered record
    Registry ID
    NCT03420469
    Conditions
    Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)
    Interventions
    Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-06-05
    Completion
    2019-05-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effect of Drug Therapy Metabolism Medications (Diagnosis)
    InterventionBupropion
    PhaseEarly phase 1
    Registry statusCompleted

  • Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

    NCT03195946 · start 2017-06-16

    Registered record
    Registry ID
    NCT03195946
    Conditions
    Drug Reactions
    Interventions
    Lu AF35700; Midazolam; Cocktail of CYP450 substrates
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-16
    Completion
    2018-01-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Reactions
    InterventionLu AF35700; Midazolam; Cocktail of CYP450 substrates
    PhasePhase 1
    Registry statusCompleted

  • Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty

    NCT02987920 · start 2017-01

    Registered record
    Registry ID
    NCT02987920
    Conditions
    Pain, Postoperative
    Interventions
    Dextromethorphan; Placebo - Concentrate; Acetaminophen; Oxycodone; Celecoxib; Pantoprazole; Ketorolac; Gabapentin; Hydromorphone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-01
    Completion
    2018-01
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative
    InterventionDextromethorphan; Placebo - Concentrate; Acetaminophen; Oxycodone +5 more
    PhasePhase 4
    Registry statusTerminated

  • An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates

    NCT02819102 · start 2016-03

    Registered record
    Registry ID
    NCT02819102
    Conditions
    Hereditary Angioedema
    Interventions
    BCX7353 and probes
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Angioedema
    InterventionBCX7353 and probes
    PhasePhase 1
    Registry statusCompleted

  • Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)

    NCT02496039 · start 2015-09

    Registered record
    Registry ID
    NCT02496039
    Conditions
    Pseudobulbar Affect (Involuntary Laughing and/or Crying)
    Interventions
    NUEDEXTA®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-09
    Completion
    2016-05
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPseudobulbar Affect (Involuntary Laughing and/or Crying)
    InterventionNUEDEXTA®
    PhasePhase 4
    Registry statusTerminated

  • Cortical Metrics in Intervention Trials With Autism Spectrum Disorders

    NCT02212275 · start 2015-08

    Registered record
    Registry ID
    NCT02212275
    Conditions
    Autism Spectrum Disorders
    Interventions
    Dextromethophan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2015-08
    Completion
    2016-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorders
    InterventionDextromethophan
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

    NCT02442765 · start 2015-07-23

    Registered record
    Registry ID
    NCT02442765
    Conditions
    Agitation in Patients With Dementia of the Alzheimer's Type
    Interventions
    AVP-786; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-07-23
    Completion
    2019-02-27
    Enrolment
    387

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAgitation in Patients With Dementia of the Alzheimer's Type
    InterventionAVP-786; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

    NCT02397382 · start 2015-06-18

    Registered record
    Registry ID
    NCT02397382
    Conditions
    Psoriasis
    Interventions
    Guselkumab; Midazolam; Warfarin; Omeprazole; Dextromethorphan; Caffeine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06-18
    Completion
    2016-08-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionGuselkumab; Midazolam; Warfarin; Omeprazole +2 more
    PhasePhase 1
    Registry statusCompleted

  • An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

    NCT02434861 · start 2015-05

    Registered record
    Registry ID
    NCT02434861
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Rolapitant; Digoxin; Sulfasalazine; Cooperstown Cocktail
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-08
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionRolapitant; Digoxin; Sulfasalazine; Cooperstown Cocktail
    PhasePhase 1
    Registry statusCompleted

  • Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination

    NCT02426983 · start 2015-04

    Registered record
    Registry ID
    NCT02426983
    Conditions
    Schizophrenia
    Interventions
    Direct Current Stimulation; Dextromethorphan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2016-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionDirect Current Stimulation; Dextromethorphan
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

    NCT02402595 · start 2015-03-01

    Registered record
    Registry ID
    NCT02402595
    Conditions
    Healthy
    Interventions
    AVP-923; AVP-786; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-03-01
    Completion
    2015-07-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionAVP-923; AVP-786; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management

    NCT02271893 · start 2014-11-25

    Registered record
    Registry ID
    NCT02271893
    Conditions
    Chemotherapy-induced Peripheral Neuropathy
    Interventions
    Dextromethorphan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-11-25
    Completion
    2022-04-21
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Peripheral Neuropathy
    InterventionDextromethorphan
    PhasePhase 2
    Registry statusTerminated

  • Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

    NCT02176018 · start 2014-08

    Registered record
    Registry ID
    NCT02176018
    Conditions
    Episodic Migraine
    Interventions
    Dextromethorphan and quinidine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08
    Completion
    2017-03
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpisodic Migraine
    InterventionDextromethorphan and quinidine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

    NCT02153502 · start 2014-07-01

    Registered record
    Registry ID
    NCT02153502
    Conditions
    Depressive Disorder, Treatment-Resistant
    Interventions
    AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-07-01
    Completion
    2016-02-01
    Enrolment
    206

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Treatment-Resistant
    InterventionAVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination); Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test

    NCT01936025 · start 2013-10

    Registered record
    Registry ID
    NCT01936025
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Dextromethorphan; Sitagliptin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionDextromethorphan; Sitagliptin; Placebo
    PhasePhase 2
    Registry statusCompleted